IFF
19.11.2020 22:17:08 CET | Business Wire | Press release
Regulatory News:
International Flavors and Fragrances (“IFF”) (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF) announced today that following a comprehensive review of the trading volume, costs and administrative requirements related to its listing on Euronext Paris, it has decided to request the voluntary delisting of its shares (the “IFF Shares”) (ISIN US4595061015) from Euronext Paris. The Board of Euronext has approved this request.
Following the delisting from Euronext Paris, the IFF Shares will remain listed on the New York Stock Exchange (the “NYSE”), IFF’s primary listing exchange.
A voluntary sales facility procedure on the NYSE will be implemented by IFF for the benefit of its shareholders holding their IFF Shares through Euroclear France (the “Euronext Shareholders”), in accordance with Euronext rules (the “Sales Facility”). Accordingly, the Euronext Shareholders will have the following options:
- decide not to participate in the voluntary sales facility and keep their IFF Shares, which they will be able to trade on Euronext Paris through and including the trading day prior to the delisting date, and thereafter, only on the NYSE; or
- participate in the voluntary sales facility described below and sell all or part of their IFF Shares on the NYSE.
Euronext Shareholders not participating
Euronext Shareholders who do not wish to sell their IFF Shares pursuant to the Sales Facility, or otherwise have taken no action to tender their IFF Shares in the Sales Facility may only trade their IFF Shares on the NYSE following the delisting date. Any such holding and/or trade will be subject to the terms applied by their financial intermediary who will take the necessary steps to move their IFF Shares from Euroclear France to the relevant alternative central system for depositary.
Participating Euronext Shareholders
Euronext Shareholders who wish to sell their IFF Shares on the NYSE pursuant to the Sales Facility must request their financial intermediaries to deliver their IFF Shares from 24th November, 2020 to 8th December, 2020 included, to BNP Paribas Securities Services, acting as centralizing agent, pursuant to the procedure described in the applicable Euronext notice expected to be published on 20th November, 2020.
The IFF Shares delivered to BNP Paribas Securities Services will be sold on the NYSE starting on Monday,14th December 2020, by a broker, at market prices prevailing at the time of the sale.
BNP Paribas Securities Services will calculate the average sale price of the IFF Shares and will be in charge of transferring the sale proceeds to the participating Euronext Shareholders, calculated on the basis of the average sale price of the IFF Shares and converted into euros.
IFF will pay the fees for the centralization and the brokerage fee related to the sale on the NYSE of the IFF Shares delivered to BNP Paribas Securities Services and sold pursuant to the Sales Facility.
Euronext Shareholders are reminded that they may tender their IFF Shares in the Sales Facility on a voluntary basis.
No assurance can be given by IFF or BNP Paribas Securities Services as to the price at which the IFF Shares will actually be sold on the NYSE, the actual average sale price or the applicable currency exchange rate. This process is being implemented solely as an option to Euronext Shareholders and participation is not mandatory. Individual investors may thus determine not to participate in this process or may decide not to take any action in which case no assurance may be given as to the terms that will be applied by their financial intermediary in connection with or after the delisting. Individual investors are invited to consult their own investment advisors before making a decision to participate or not in this process.
The timetable of the Sales Facility and the delisting described above may be summarized as follows (it being specified that IFF reserves the right to amend this timetable):
Sales Facility |
|
Beginning of the Sales Facility
|
Tuesday 24th November 2020 (Tender period of 10 trading days) |
End of the Sales Facility |
Tuesday 8th December 2020 |
End of the centralization by BNP Paribas Securities Services |
Friday 11th December 2020 |
Sales on the New York Stock Exchange of the IFF Shares tendered in the Sales Facility |
Starting on Monday 14th December 2020 |
Proceeds of sale in USD converted into Euros |
Upon receipt of the funds by the bank |
Proceeds of sale distributed to the beneficiaries (i.e. , holders of IFF Shares having participated in the Sales Facility) |
Upon receipt of the funds by the bank |
Delisting |
|
Last day of trading of IFF Shares on Euronext Paris |
Thursday 17th December 2020 |
Delisting of IFF Shares from Euronext Paris |
Friday 18th December 2020 |
Euronext Shareholders participating in the Sales Facility acknowledge and agree to assume the risks associated with changes in the market price of IFF Shares and currency exchange rates that may occur between the time IFF Shares are delivered to BNP Paribas Securities Services and the sale of such IFF Shares on the NYSE as well as the date of conversion of the price into euros. All tender instruction of IFF Shares under the Sales Facility are irrevocable.
IFF Shares will be delisted from Euronext Paris on 18th December, 2020. IFF Shares will continue to be listed on the NYSE under the symbol “IFF”.
Shareholders are invited to contact their financial intermediaries for any additional information.
Welcome to IFF
At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
Important Information
This press release is for information purposes only and does not constitute or form part of any advertisement, offer, solicitation or an invitation to make offers, sell, exchange or transfer, or any solicitation of any offer to subscribe for or purchase, or advertisement of, any securities, nor shall it (or any part of it) form the basis of any investment decision, contract or commitment whatsoever, and is provided for information only. The distribution of this press release may be restricted by law in certain jurisdictions, and persons into whose possession this press release or other information referred to herein come should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdiction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119006199/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bial Reports Topline Results From ACTIVATE Phase 2b Study in GBA‑Associated Parkinson’s9.6.2026 08:00:00 CEST | Press release
Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced today that the Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s who have a pathogenic variant in the GBA1 gene (GBA-PD) did not meet its primary, nor the key secondary efficacy endpoints, meaning that BIA 28-6156 failed to slow the progression of GBA-PD versus placebo. BIA 28-6156 proved to be generally well tolerated in the study, with no unexpected safety concerns arising. While the study data provide valuable scientific information and contribute to a broader understanding of Parkinson’s biology, BIA 28-6156 did not demonstrate significant differentiation from placebo on the primary or key secondary endpoints measured. Based on the lack of demonstrated efficacy in this study, Bial has made the decision to discontinue further development of BIA 28-6156 for this indication. “We are disappointed with the outcome of the Phase 2b ACTIVATE study, as th
Avanzanite Expands into Spain and Appoints María Baquerizo as Country Manager9.6.2026 07:30:00 CEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into Spain and the appointment of María Baquerizo López-Quectuy as Spain Country Manager. This follows a €32 million Series A investment by MVM Partners announced in November 2025 and the recent entry to France. Avanzanite’s continues to build its integrated European platform designed to accelerate access to innovative therapies for people living with rare diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608541655/en/ María Baquerizo López-Quectuy, Country Manager, Avanzanite Spain “Spain is an essential part of Avanzanite’s European vision,” said Adam Plich, Co-Founder and CEO, Avanzanite Bioscience. “The country combines scientific excellence, a sophisticated healthcare ecosystem and a large community of patients living with rare diseases who continue to
Cursor Announces EMEA Office and Team Expansion to Meet Regional Demand9.6.2026 07:00:00 CEST | Press release
London headquarters will open this summer and grow to approximately 200 employees by year-end as EMEA becomes Cursor's fastest-growing region Cursor, the leading multi-model AI coding platform, today announced the establishment of dedicated teams to serve the EMEA region. The expansion responds to regional momentum, with EMEA revenue tripling quarter over quarter this year. The Cursor EMEA team will support a rapidly expanding customer base that includes British Airways, BP, Deliveroo, Nokia, Sanofi and many other leading enterprises across the region. Cursor expects to grow its EMEA headcount to approximately 200 employees by the end of the year, hiring across go-to-market, engineering, customer success and operations. “We’re incredibly excited to officially launch Cursor across EMEA and deepen our commitment to customers and partners throughout Europe. As the leading AI coding company, our goal is simple: be closer to the teams building the future and help enterprises accelerate thei
Signaloid to Preview New ASIC and Demo of Its UxHw® Technology at Bosch Connected World9.6.2026 07:00:00 CEST | Press release
British AI hardware company Signaloid will preview its recently-taped-out ASIC for physical AI at Bosch Connected World, from 10th–11th June 2026, in Berlin.The ASIC is complementary to Signaloid’s edge hardware modules which are already achieving over 37-fold speedup for algorithms used in physical AI and robotics. British computing technology company Signaloid will preview its C0-ASIC for physical AI this week at Bosch Connected World, taking place from 10th-11th June, in Berlin. Designed for robotics, industrial automation, and probabilistic AI workloads, the ASIC is projected to deliver up to 1000× better performance-per-Watt than existing state-of-the-art approaches. Signaloid’s distribution-extended compute hardware (UxHw®) is already available for use in physical AI/robotics as a family of hardware modules, as well as via a virtualization- and binary-translation-based solution. UxHw enables autonomous mobile robots (AMRs) to improve their navigation algorithms for safer and fast
Hitachi and Google Cloud Expand Strategic Alliance to Accelerate Real-world Deployment of Physical AI Through FDE and Advanced Cybersecurity Solutions9.6.2026 02:20:00 CEST | Press release
Hitachi and Google Cloud will bolster FDE capabilities to accelerate physical AI globally by combining Hitachi’s co-creation approach and digital engineering capabilities cultivated through Lumada with Google Cloud’s advanced AI. Through the development of these FDE capabilities, Hitachi and Google Cloud will enhance HMAX using Gemini Enterprise, helping solve frontline worker challenges through autonomous operations in complex environments. By scaling FDE knowledge, Hitachi will deliver value to a wider range of customers. Expanding the collaboration, Hitachi and Google Cloud will enable customers to bolster their cyber defense capabilities against AI-driven cyber threats. Hitachi, Ltd. (TSE:6501, "Hitachi") today announced the expansion of its strategic alliance*1 with Google Cloud to support customers by accelerating the real-world deployment of physical AI and cybersecurity solutions to protect against AI generated threats. Garnering increasing attention, physical AI is a technolog
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom